Smith, Jaclyn A.
Stein, Norman
Migas, Sylwia
Bokowski, Sue
Williams, Claire
Baker, Patricia
New, John
Schelfhout, Jonathan
Fonseca, Eileen
Langerman, Haya
Funding for this research was provided by:
Merck Sharp & Dohme LLC
Article History
Received: 10 November 2023
Accepted: 12 June 2024
First Online: 4 July 2024
Declarations
:
: Approval from the Health Research Authority (HRA), and South Central - Hampshire A Research Ethics Committee was sought and obtained prior to any study activities commencing. Patients or the public were not involved in the design, conduct, reporting or dissemination plans of our research. Written informed consent was obtained from all patients who participated in the study, except for the control cohort, which was an anonymised dataset.
: Not applicable.
: JAS has received funding for consultancy, lectures and for the delivery of clinical trials from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. She has also received funding for consultancy and clinical trial delivery from Bayer, Bellus Health, Shionogi, Nocion Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals and consultancy fees from Astra Zeneca and Boehringer Ingelheim. NS, SM, SB, CW, PB are employees of NWEH. NWEH was contracted by Merck, Sharp & Dohme Limited in connection with this study. NS received no additional funding nor provision outside of normal NWEH salary arrangements. JS and EF are employees of Merck Sharpe & Dohme, LLC, a subsidiary of Merck & Co. Inc. HL is an employee of Merck Sharpe & Dohme, UK. JN has no conflicts of interest related to this work.